ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 152 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 2.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,775 | -47.8% | 696 | 0.0% | 0.00% | -42.9% |
| Q2 2023 | $14,895 | -47.1% | 696 | 0.0% | 0.01% | -50.0% |
| Q1 2023 | $28,147 | -13.1% | 696 | 0.0% | 0.01% | -17.6% |
| Q4 2022 | $32,378 | -10.1% | 696 | 0.0% | 0.02% | -10.5% |
| Q3 2022 | $36,000 | +9.1% | 696 | 0.0% | 0.02% | +11.8% |
| Q2 2022 | $33,000 | -34.0% | 696 | 0.0% | 0.02% | -26.1% |
| Q1 2022 | $50,000 | -3.8% | 696 | 0.0% | 0.02% | 0.0% |
| Q4 2021 | $52,000 | +30.0% | 696 | 0.0% | 0.02% | +15.0% |
| Q3 2021 | $40,000 | +29.0% | 696 | 0.0% | 0.02% | +25.0% |
| Q2 2021 | $31,000 | -8.8% | 696 | 0.0% | 0.02% | -15.8% |
| Q1 2021 | $34,000 | +17.2% | 696 | 0.0% | 0.02% | +11.8% |
| Q4 2020 | $29,000 | -9.4% | 696 | 0.0% | 0.02% | -19.0% |
| Q3 2020 | $32,000 | -8.6% | 696 | 0.0% | 0.02% | -19.2% |
| Q2 2020 | $35,000 | -2.8% | 696 | 0.0% | 0.03% | -18.8% |
| Q1 2020 | $36,000 | -16.3% | 696 | 0.0% | 0.03% | +3.2% |
| Q4 2019 | $43,000 | – | 696 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 936,777 | $53,218,000 | 16.69% |
| Fairmount Funds Management LLC | 316,952 | $18,006,000 | 6.55% |
| ARMISTICE CAPITAL, LLC | 1,836,000 | $104,303,000 | 1.77% |
| Soleus Capital Management, L.P. | 182,400 | $10,362,000 | 1.62% |
| Portland Global Advisors LLC | 62,635 | $3,558,000 | 0.66% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 40,000 | $2,263,000 | 0.55% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,995,000 | $113,336,000 | 0.53% |
| Yorktown Management & Research Co Inc | 10,400 | $591,000 | 0.44% |
| Hennion & Walsh Asset Management, Inc. | 120,240 | $6,831,000 | 0.36% |
| Virtus ETF Advisers LLC | 9,599 | $545,000 | 0.24% |